Ken is a serial entrepreneur, having co-founded 10 biotech companies over his career, mostly in the field of infectious diseases. Today he represents IDBiologics, which is developing fully human, ultra-potent monoclonal antibodies to prevent influenza (and other respiratory diseases). Ken is also Chairman of XCMR, Inc which is developing radically improved persona protective equipment (PPE) to kill airborne viruses in lieu of wearing an N95 mask. Ken took his first company IntraBiotics, an antibiotic company, public on the Nasdaq in 2000. He sold his second, Fluxion Biosciences, and third, PaxVax, and remains chairman of Appel Sauce Studios, IDBiologics, Selva Therapeutics, SeromYx Systems, and XCMR. Ken was a Harvard Advanced Leadership Initiative Fellow (2015), an AIMBE (American Institute for Medical and Biological Engineers) 2016 and a White House Presidential Executive Fellow (2016-2017). Earlier in his career, Ken was biotech venture capitalist with 20+ years of Ser A investing experience in 48 companies with more than 36 successful IPOs or M&A exits at Institutional Venture Partners (IVP), Latterell Venture Partners (LVP) and his own fund (K2 BioVentures).